Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage
Published Date: 1/30/2026
Proposed Rule
Summary
This new rule updates the rules for Organ Procurement Organizations (OPOs) that help collect and share organs for transplants. It adds clearer guidelines, new quality checks, and updates how OPOs compete and appeal decisions to boost organ donations and save more lives. OPOs and transplant patients will feel the impact, with comments open until March 31, 2026, and no new costs announced yet.
Analyzed Economic Effects
9 provisions identified: 3 benefits, 2 costs, 4 mixed.
New Rules for DSA Designation and Competition
CMS would allow an OPO to be designated to more than one Donation Service Area (DSA) and would evaluate each DSA separately on outcome measures while evaluating process performance measures across the OPO's entire organization. CMS would also enable selective removal of an OPO's designation for a DSA where it underperforms and would open tier 2 DSAs for competition from other OPOs.
New QAPI Rules for Complex Organs
OPOs would be required to include medically complex donors and medically complex organs in their Quality Assessment and Performance Improvement (QAPI) programs. Each OPO must annually count medically complex donors from whom it obtained consent, the number of organs recovered from those donors, and the number of medically complex organs transplanted, and must act to improve performance when it finds opportunities.
CMS May Certify New OPOs
CMS proposes to remove Sec. 486.303(e) so the Secretary may certify new Organ Procurement Organizations (OPOs) after January 1, 2000, reversing CMS's prior interpretation. This change would allow certification of new OPO entities.
New Definition for Unsound Medical Practices
CMS proposes to define "unsound medical practices" as failures by OPOs that create an imminent threat to patient health and safety or pose a risk to patients or the public, including failures in governance; donor evaluation and management; and procurement, allocation, and transport practices. Such practices are examples of circumstances that could lead CMS to de-certify an OPO under "urgent need."
Estimated Sector Costs and Benefits
CMS estimates the proposed rule would impose $19.1 million in Year 1 and $6.3 million in subsequent years. Year 1 costs are estimated at $17.9 million for OPOs and $1.2 million for CMS; recurring annual costs are approximately $6.2 million for OPOs and $331,000 for CMS. Quantified benefits are estimated at $884,000 annually plus a one-time benefit of $300,000.
When Successor OPOs Are Held Accountable
The proposed rule would revise when CMS will hold an OPO accountable on outcome measures after it takes over another OPO's DSA and discusses factors CMS would consider when selecting a successor OPO during competition under the tiered re-certification approach.
How Pancreas Research Counts Toward Rates
The proposal would count an individual whose pancreas is procured and used for islet cell research as a "donor" for the donation rate outcome measure, but would remove pancreata used for research from the definition of "organ" and thus exclude them from the organ transplantation rate outcome measure. OPOs would also be required to keep records for organs procured for research, including pancreata used for islet cell research.
Appeals Process and Timing Changes
The proposed rule revises Sec. 486.314 to allow appeals of de-certification and removal of designation to a tier 3 DSA without de-certification, changes all time periods from "business days" to "calendar days," shortens some timeframes, and would codify a CMS Administrator discretionary review with set review periods and possible remand.
Staff Licensure and Scope Requirements
OPOs would be required to assure current State or local licensure, certification, or registration of staff who furnish clinical services, and ensure personnel performing clinical duties act within the scope of that licensure, certification, or registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14709, Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program; Correction
This correction fixes some typos and technical mistakes in the 2027 health insurance rules under the Affordable Care Act. It mainly affects people and organizations involved in health coverage plans by clarifying when the rules take effect and restoring some important regulation details. These fixes take effect on July 20, 2026, ensuring smoother and clearer health plan operations next year.
2026-12069, Medicare Program; Strengthening Oversight of Accrediting Organizations (AOs) and Preventing AO Conflicts of Interest, and Related Provisions
This new rule makes sure the groups that check Medicare providers play fair and follow clear rules to avoid conflicts of interest. It updates how psychiatric hospitals are reviewed and tightens rules for providers who lost their Medicare status but want back in. These changes affect Medicare providers and accrediting groups, start June 16, 2027, and aim to keep care safe and trustworthy.
2026-10890, Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model
Starting July 1, 2026, Medicare is updating the Increasing Organ Transplant Access (IOTA) Model to help kidney transplant hospitals do even better at getting more people transplanted and improving care quality. These changes affect hospitals involved in kidney transplants and aim to make the process smoother and more effective, with new payment rules that reward success. This update is part of a 6-year plan running through 2031 to save more lives and boost patient experience.
2026-10292, Medicaid Program; Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Medicaid Practitioner Payments
This proposed rule changes how states can pay Medicaid managed care plans and certain doctors to make sure payments are fair, efficient, and encourage enough providers to offer quality care. It affects states, Medicaid managed care organizations, and targeted Medicaid practitioners, aiming to keep payments balanced and services available. Comments on these changes are open until July 21, 2026, so stakeholders have time to weigh in before it’s finalized.
2026-10050, Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program
Starting in 2027, health insurance plans on federal and state marketplaces will see new rules to make coverage fairer and easier to use. These changes affect insurance companies, agents, and people buying plans, including new fees, penalties, and better protections for those with hardships. Expect updates on plan quality, dental coverage limits, and longer-term catastrophic plans, all aiming to keep your health coverage solid and affordable.
2026-07205, Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges
This new rule will help Medicare, Medicaid, CHIP, and health plan companies share patient info more easily and speed up drug approval requests. It affects Medicare Advantage, Medicaid, CHIP, and health plans on federal exchanges, aiming to make care smoother and faster. These changes will start soon and could save time and money by cutting red tape.
Previous / Next Documents
Previous: 2026-01817, Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMP
The government wants your thoughts on updating rules that stop sneaky deals and freebies in Medicare and state health programs, especially for new drug sales like those on TrumpRx. This could change how drug companies sell directly to patients, making meds fairer and cheaper for Americans. Speak up by March 30, 2026, to help shape these important changes that could save money and protect patients.
Next: 2026-01844, Interstate Transport Plan Review for the 2015 Ozone NAAQS
The EPA is proposing to approve air quality plans from eight states to help reduce ozone pollution that crosses state lines. This means Alabama, Arizona, Kentucky, Minnesota, Mississippi, Nevada, New Mexico, and Tennessee are on track to keep their air cleaner and not harm their neighbors. If finalized, this will clear up pollution rules for these states and drop some earlier penalties, with public comments open until March 2, 2026.